A Phase 3 interventional study of Probiotic Arm and Placebo Arm in Mild and Moderate Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-07-27.
Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Lymphoma, Follicular with a site in India — 4 open to participants now, 4 under way, 2 of them phase 3. Lymphoma, Follicular · India.
Among the 15 studies in Lymphoma, Follicular with a site in India, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 6th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →4 of the 15 studies in Lymphoma, Follicular with a site in India are open now. Recruiting first, the newest first:
Celgene · Sites in India, United States, Australia and 18 more countries
Ages 18+
AstraZeneca · Sites in India, United States, Australia and 22 more countries
Ages 18–130
Aurigene Discovery Technologies Limited · Sites in India
Ages 18–99
Biotech Healthcare Holding Gmbh · Sites in India, Germany
Ages 21+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 213 across the 13 interventional studies, 711 across the 2 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 10 most frequent:
CD Pharma India Pvt. Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
CD Pharma India Pvt. Ltd. has 1 study filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
1 of the studies in Lymphoma, Follicular with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05984147Aurigene Discovery Technologies LimitedA Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) | 2027-08-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Lymphoma, Follicular with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The oral cavity is mostly influenced by general health. The oral microbiota which is as complex as the gastro-intestinal or vaginal microbiota are considered to be difficult therapeutic targets. The effects of probiotics in different fields of health care have resulted recently in the introduction of probiotics for oral healthcare. Probiotics have been clinically proved effective in different fields of oral healthcare such as halitosis, oral candidiasis and tooth decay. They have also been inducted in the field of periodontal healthcare because of the current views on the etiology of plaque- related periodontal inflammation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
Drug: Probiotic Arm
Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
Drug: Placebo Arm
Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
Improvement in Clinical Periodontal Indices
Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), Bleeding on Probing (BOP)
Time frame: 8 weeks
Improvement in Biochemical Indices
Changes in levels of Inflammatory markers, namely, Interleukin 1β, Matrix metalloproteinases-8 (MMP), Myeloperoxidase (MPO) and Calprotectin in Gingival Crevicular Fluid (GCF)
Time frame: 8 weeks
The record gives a start of Jan 2015, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
CD Pharma India Pvt. Ltd.